Which has stronger earnings & valuation, OMER or CABA?

Cabaletta Bio is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omeros N/A N/A -$3.35M $1.28 14.75 Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A

Is OMER or CABA more profitable?

Cabaletta Bio's return on equity of -128.27% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -164.92% 69.41% Cabaletta Bio N/A -128.27% -95.47%

Does the media refer more to OMER or CABA?

In the previous week, Omeros and Omeros both had 2 articles in the media. Cabaletta Bio's average media sentiment score of 1.80 beat Omeros' score of 0.37 indicating that Cabaletta Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cabaletta Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation and earnings, CABA or KLRA?

Cabaletta Bio is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A Kailera Therapeutics N/A N/A -$148.96M -$3.65 thousand N/A

Is CABA or KLRA more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -128.27% -95.47% Kailera Therapeutics N/A N/A N/A

Does the media prefer CABA or KLRA?

In the previous week, Kailera Therapeutics had 5 more articles in the media than Cabaletta Bio. MarketBeat recorded 7 mentions for Kailera Therapeutics and 2 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 1.80 beat Kailera Therapeutics' score of 0.85 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Kailera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, NBTX or CABA?

Nanobiotix has higher revenue and earnings than Cabaletta Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 29.50 -$27.11M N/A N/A Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A

Is NBTX or CABA more profitable?

Nanobiotix's return on equity of 0.00% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Cabaletta Bio N/A -128.27% -95.47%

Which has higher valuation & earnings, DMRA or CABA?

Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$3.37 N/A Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A

Is DMRA or CABA more profitable?

Cabaletta Bio's return on equity of -128.27% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -176.39% -77.86% Cabaletta Bio N/A -128.27% -95.47%

Does the media refer more to DMRA or CABA?

In the previous week, Damora Therapeutics, Inc. Common Stock had 2 more articles in the media than Cabaletta Bio. MarketBeat recorded 4 mentions for Damora Therapeutics, Inc. Common Stock and 2 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 1.80 beat Damora Therapeutics, Inc. Common Stock's score of 0.60 indicating that Cabaletta Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Damora Therapeutics, Inc. Common Stock 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cabaletta Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings & valuation, CABA or ORIC?

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A

Is CABA or ORIC more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -128.27% -95.47% Oric Pharmaceuticals N/A -35.35% -33.39%

Does the media prefer CABA or ORIC?

In the previous week, Cabaletta Bio and Cabaletta Bio both had 2 articles in the media. Cabaletta Bio's average media sentiment score of 1.80 beat Oric Pharmaceuticals' score of 0.48 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Oric Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Cabaletta Bio (CABA) Competitors

$1.58 -0.11 (-6.21%)

As of 11:33 AM Eastern

Compare

CABA vs. OMER, KLRA, NBTX, DMRA, and ORIC

Should you buy Cabaletta Bio stock or one of its competitors? Cabaletta Bio's main competitors and comparable companies include Omeros (OMER), Kailera Therapeutics (KLRA), Nanobiotix (NBTX), Damora Therapeutics, Inc. Common Stock (DMRA), and Oric Pharmaceuticals (ORIC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cabaletta Bio compare to Omeros?

Omeros (NASDAQ:OMER) and Cabaletta Bio (NASDAQ:CABA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

48.8% of Omeros shares are held by institutional investors. 10.5% of Omeros shares are held by insiders. Comparatively, 6.4% of Cabaletta Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Omeros and Omeros both had 2 articles in the media. Cabaletta Bio's average media sentiment score of 1.80 beat Omeros' score of 0.37 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cabaletta Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cabaletta Bio's return on equity of -128.27% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-164.92%	69.41%
Cabaletta Bio	N/A	-128.27%	-95.47%

Omeros has a beta of 2.57, suggesting that its share price is 157% more volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.48, suggesting that its share price is 248% more volatile than the broader market.

Cabaletta Bio is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$1.28	14.75
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A

Omeros presently has a consensus target price of $34.00, indicating a potential upside of 80.08%. Cabaletta Bio has a consensus target price of $15.60, indicating a potential upside of 823.08%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, analysts clearly believe Cabaletta Bio is more favorable than Omeros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

Cabaletta Bio beats Omeros on 7 of the 12 factors compared between the two stocks.

How does Cabaletta Bio compare to Kailera Therapeutics?

Cabaletta Bio (NASDAQ:CABA) and Kailera Therapeutics (NASDAQ:KLRA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Cabaletta Bio presently has a consensus price target of $15.60, indicating a potential upside of 823.08%. Kailera Therapeutics has a consensus price target of $42.75, indicating a potential upside of 296.94%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Cabaletta Bio is more favorable than Kailera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Kailera Therapeutics had 5 more articles in the media than Cabaletta Bio. MarketBeat recorded 7 mentions for Kailera Therapeutics and 2 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 1.80 beat Kailera Therapeutics' score of 0.85 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Kailera Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cabaletta Bio is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A

Kailera Therapeutics' return on equity of 0.00% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-128.27%	-95.47%
Kailera Therapeutics	N/A	N/A	N/A

Summary

Cabaletta Bio beats Kailera Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Cabaletta Bio compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Cabaletta Bio (NASDAQ:CABA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Nanobiotix has higher revenue and earnings than Cabaletta Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	29.50	-$27.11M	N/A	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A

Nanobiotix's return on equity of 0.00% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Cabaletta Bio	N/A	-128.27%	-95.47%

38.8% of Nanobiotix shares are held by institutional investors. 3.5% of Nanobiotix shares are held by company insiders. Comparatively, 6.4% of Cabaletta Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Nanobiotix presently has a consensus price target of $46.67, indicating a potential upside of 117.16%. Cabaletta Bio has a consensus price target of $15.60, indicating a potential upside of 823.08%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Nanobiotix has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.48, meaning that its share price is 248% more volatile than the broader market.

In the previous week, Cabaletta Bio had 1 more articles in the media than Nanobiotix. MarketBeat recorded 2 mentions for Cabaletta Bio and 1 mentions for Nanobiotix. Cabaletta Bio's average media sentiment score of 1.80 beat Nanobiotix's score of 0.89 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Nanobiotix	Positive
Cabaletta Bio	Very Positive

Summary

Cabaletta Bio beats Nanobiotix on 8 of the 13 factors compared between the two stocks.

How does Cabaletta Bio compare to Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Cabaletta Bio (NASDAQ:CABA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Comparatively, 6.4% of Cabaletta Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Damora Therapeutics, Inc. Common Stock currently has a consensus target price of $46.50, indicating a potential upside of 150.54%. Cabaletta Bio has a consensus target price of $15.60, indicating a potential upside of 823.08%. Given Cabaletta Bio's higher probable upside, analysts clearly believe Cabaletta Bio is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

In the previous week, Damora Therapeutics, Inc. Common Stock had 2 more articles in the media than Cabaletta Bio. MarketBeat recorded 4 mentions for Damora Therapeutics, Inc. Common Stock and 2 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 1.80 beat Damora Therapeutics, Inc. Common Stock's score of 0.60 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cabaletta Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Damora Therapeutics, Inc. Common Stock has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.48, indicating that its share price is 248% more volatile than the broader market.

Cabaletta Bio's return on equity of -128.27% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%
Cabaletta Bio	N/A	-128.27%	-95.47%

Summary

Cabaletta Bio beats Damora Therapeutics, Inc. Common Stock on 7 of the 13 factors compared between the two stocks.

How does Cabaletta Bio compare to Oric Pharmaceuticals?

Cabaletta Bio (NASDAQ:CABA) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

Cabaletta Bio has a beta of 3.48, meaning that its share price is 248% more volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

Oric Pharmaceuticals' return on equity of -35.35% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-128.27%	-95.47%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

95.1% of Oric Pharmaceuticals shares are held by institutional investors. 6.4% of Cabaletta Bio shares are held by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cabaletta Bio currently has a consensus price target of $15.60, indicating a potential upside of 823.08%. Oric Pharmaceuticals has a consensus price target of $20.67, indicating a potential upside of 82.73%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

In the previous week, Cabaletta Bio and Cabaletta Bio both had 2 articles in the media. Cabaletta Bio's average media sentiment score of 1.80 beat Oric Pharmaceuticals' score of 0.48 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Oric Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cabaletta Bio and Oric Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

Get Cabaletta Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CABA vs. The Competition

Export

Metric	Cabaletta Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$272.11M	$3.88B	$7.26B	$13.10B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-1.02	13.21	275.54	25.58
Price / Sales	N/A	1,131.68	557.67	80.26
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	1.38	17.16	10.81	6.02
Net Income	-$167.86M	-$22.65M	$3.49B	$380.34M
7 Day Performance	-18.53%	-4.64%	-3.00%	-3.19%
1 Month Performance	-44.85%	-12.66%	-7.48%	-6.07%
1 Year Performance	-44.46%	8.08%	3.18%	-3.77%

Cabaletta Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CABA Cabaletta Bio	2.9133 of 5 stars	$1.59 -6.2%	$15.60 +884.2%	-32.1%	$268.72M	N/A	N/A	158	News Coverage Positive News Gap Down
OMER Omeros	3.7819 of 5 stars	$18.90 +1.6%	$34.00 +79.9%	+350.6%	$1.35B	N/A	14.77	175	Analyst Forecast
KLRA Kailera Therapeutics	2.3876 of 5 stars	$10.84 +4.3%	$42.75 +294.4%	N/A	$1.35B	N/A	N/A	145	Lockup Expiration
NBTX Nanobiotix	3.3417 of 5 stars	$25.10 -2.5%	$46.67 +85.9%	-29.1%	$1.30B	$36.87M	N/A	97
DMRA Damora Therapeutics, Inc. Common Stock	3.2215 of 5 stars	$20.22 -2.1%	$46.50 +130.0%	+45.6%	$1.27B	N/A	N/A	40	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CABA) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cabaletta Bio (CABA) Competitors

CABA vs. OMER, KLRA, NBTX, DMRA, and ORIC

How does Cabaletta Bio compare to Omeros?

Summary

How does Cabaletta Bio compare to Kailera Therapeutics?

Summary

How does Cabaletta Bio compare to Nanobiotix?

Summary

How does Cabaletta Bio compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Cabaletta Bio compare to Oric Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA vs. The Competition

Cabaletta Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cabaletta Bio (CABA) Competitors

CABA vs. OMER, KLRA, NBTX, DMRA, and ORIC

How does Cabaletta Bio compare to Omeros?

Do insiders and institutionals believe in OMER or CABA?

Does the media refer more to OMER or CABA?

Is OMER or CABA more profitable?

Which has more risk & volatility, OMER or CABA?

Which has stronger earnings & valuation, OMER or CABA?

Do analysts prefer OMER or CABA?

Summary

How does Cabaletta Bio compare to Kailera Therapeutics?

Do analysts rate CABA or KLRA?

Does the media prefer CABA or KLRA?

Which has higher valuation and earnings, CABA or KLRA?

Is CABA or KLRA more profitable?

Summary

How does Cabaletta Bio compare to Nanobiotix?

Which has better earnings & valuation, NBTX or CABA?

Is NBTX or CABA more profitable?

Do institutionals and insiders believe in NBTX or CABA?

Do analysts recommend NBTX or CABA?

Which has more volatility & risk, NBTX or CABA?

Does the media refer more to NBTX or CABA?

Summary

How does Cabaletta Bio compare to Damora Therapeutics, Inc. Common Stock?

Which has higher valuation & earnings, DMRA or CABA?

Do institutionals & insiders believe in DMRA or CABA?

Do analysts recommend DMRA or CABA?

Does the media refer more to DMRA or CABA?

Which has more volatility and risk, DMRA or CABA?

Is DMRA or CABA more profitable?

Summary

How does Cabaletta Bio compare to Oric Pharmaceuticals?

Which has more risk and volatility, CABA or ORIC?

Which has stronger earnings & valuation, CABA or ORIC?

Is CABA or ORIC more profitable?

Do insiders & institutionals have more ownership in CABA or ORIC?

Do analysts prefer CABA or ORIC?

Does the media prefer CABA or ORIC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA vs. The Competition

Cabaletta Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools